NTHU
2.12.2021 11:02:13 CET | Business Wire | Press release
National Tsing Hua University (NTHU) was awarded the Taiwan University Sustainability Award at the 14th Taiwan Corporate Sustainability Awards (TCSA) held by the Taiwan Institute for Sustainable Energy (TAISE) on November 17. Standing out amongst the 38 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions also received the Social Inclusion Leadership Award and the University Sustainability Report Gold Award.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005031/en/
The judges cited the exemplary way in which NTHU has built on its core competence in teaching and research to respond with concrete actions in meeting the requirements of sustainable development, including the implementation of a campus-wide campaign for reducing energy consumption and carbon emissions. In addition, they were impressed by NTHU’s workplace ethics emphasizing diversity and equality, as well as the way in which faculty and staff are rewarded for outstanding performance in research, teaching, counseling, and public service, all of which has had a positive impact on the larger society and enhanced the university’s international profile. In terms of sustainability, NTHU has consistently demonstrated what is meant by its school motto, “To Oneself Be True, Give Nature Its Due.”
President Hocheng Hong said that the natural beauty of the campus goes hand-in-hand with the principles of sustainability. In addition to being the first university in Taiwan to appoint a chief sustainability officer, NTHU has a total of 517 undergraduate courses related to sustainability, and 216 at the graduate level, which together amount to 13% of the school’s courses.
NTHU senior vice president and chief sustainability officer Tai Nyan-hwa pointed out that in order to deepen the concept of sustainability on all levels, each administrative and academic department has appointed a sustainability officer, all 26 of whom belong to the Sustainability Committee, which meets every two months to discuss the latest developments and coordinate their efforts.
Sustainability Office director Lin Fu-ren said that since research, teaching, and public service are the most important tasks of a university, the school’s early efforts in promoting sustainability focused on encouraging teachers, researchers, and students to integrate the principles of sustainability into their ongoing work. Numerous faculty members at NTHU are conducting research directly related to the 17 goals of sustainable development promulgated by the United Nations. In the process, they have demonstrated how focusing attention on an issue generates positive change.
Lin said that in addition to the ongoing Rising Sun Scholarship for financially disadvantaged students, NTHU has established a special fund for assisting students undergoing hardship due to the COVID-19 pandemic, both of which tie in with the UN’s sustainability goals of “no poverty” and “quality education.”
Lin also pointed out that making sustainable development a reality requires planting the seeds of sustainability in the hearts of students, so that when they graduate, these seeds will sprout and grow strong throughout society.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005031/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom